TYRA — Tyra Biosciences, Inc. stock price, charts and financials

Latest market price

32.53

+0.49+1.53%

Overview Short InterestFilings

TYRAQT86Tyra Biosciences, Inc.·NASDAQ

Overview Short InterestFilings

32.53+1.53%

Filing

Up 1.5% — Filed an 8-K material-event report (2026-08-04) — details in the filing.

Medium confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

URGN+3.45%$39.92 IOVA+0.93%$4.36 AUPH+2.47%$14.93 MESO+2.28%$14.80 STOK+7.14%$31.67 TSHA+7.27%$6.20 ZBIO+0.93%$31.42 OCUL+2.26%$8.59

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	59.47M	Perf Week	5.34%

Market Cap	1.93B	Forward P/E	-	EPS next Y	-2.87	Insider Trans	-0.05%	Shs Float	44.18M	Perf Month	5.41%

Enterprise Value	1.56B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	22.48%	Perf Quarter	-7.43%

Income	-120.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	10.65	Perf Half Y	4.87%

Sales	0.00	P/B	4.99	EPS next Y	-11.07%	ROA	-31.82%	Short Interest	9.93M	Perf YTD	23.74%

Book/sh	6.52	P/C	5.05	EPS next 5Y	-	ROE	-42.66%	52W High	40.65 -19.98%	Perf Year	213.69%

Cash/sh	6.44	P/FCF	-	EPS past 3/5Y	-	ROIC	-36.34%	52W Low	9.96 226.61%	Perf 3Y	126.69%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	5.41% 5.30%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-44.37%	Oper. Margin	0.00%	ATR (14)	1.70	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	20.49	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	55.87	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	20.49	EPS Q/Q	-36.17%	SMA20	2.06%	Beta	0.53	Target Price	50.67

Payout	0.00%	Debt/Eq	0.02	Sales Q/Q	-	SMA50	6.34%	Rel Volume	0.44	Prev Close	32.04

Employees	87	LT Debt/Eq	0.02	Earnings	Aug 13	SMA200	11.98%	Avg Volume	800.99K	Price	32.53

IPO Date	Sep 15, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.83% -	Net Debt/EBITDA	0.61	Volume	350,204	Change	1.53%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Apr-14-26	Initiated	Guggenheim	Buy	$54
Feb-17-26	Reiterated	HC Wainwright & Co.	Buy	$30 → $45
Feb-13-26	Reiterated	Wedbush	Outperform	$37 → $53
Feb-03-26	Reiterated	Oppenheimer	Outperform	$36 → $50
Jan-27-26	Initiated	Barclays	Overweight	$59
Jan-23-26	Reiterated	Piper Sandler	Overweight	$42
Dec-16-25	Reiterated	Wedbush	Outperform	$37
Sep-10-25	Reiterated	Oppenheimer	Outperform	$30 → $36
Nov-11-24	Reiterated	HC Wainwright & Co.	Buy	$25 → $30
Oct-18-24	Reiterated	Bank of America Securities		$31

Latest News

Aug-04-26

Aug-04-2604:05PM

Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlightsprnewswire.com

Jun-23-26

Jun-23-2602:31PM

Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsightYahoo

Jun-12-26

Jun-12-2608:50AM

TD Synnex To Rally More Than 8%? Here Are 10 Top Analyst Forecasts For FridayBenzinga

Jun-11-26

Jun-11-2607:49AM

Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For ThursdayBenzinga

Jun-10-26

Jun-10-2608:24AM

Micron Technology To $900? Here Are 10 Top Analyst Forecasts For WednesdayBenzinga

07:33AM

B of A Securities Maintains Buy on Tyra Biosciences, Raises Price Target to $42Benzinga

Company

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	0	0	0	0	0	0	0
Cost of Goods Sold Incl. D&A	0	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0	0
Selling, General and Administrative Excl. Other	30	24	17	16	6	2	1
Research and Development	103	80	63	43	21	7	2
Other Operating Expense	0	0	0	0	-1	0	0
Operating Income	-133	-104	-80	-59	-26	-9	-3
Interest Expense	0	0	0	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—
Non-Operating Income (Expense)	13	18	11	4	0	0	-1
Net Income Before Taxes	-120	-86	-69	-55	-26	-9	-4
Income Taxes	0	0	0	0	0	0	0
Consolidated Net Income	-120	-86	-69	-55	-26	-9	-4
Net Income From Continuing Operations	-120	-86	-69	-55	-26	-9	-4
Net Income	-120	-86	-69	-55	-26	-9	-4
EPS (Recurring)	-2.01	-1.51	-1.62	-1.23	-0.63	-0.22	-0.10
EPS (Basic, Before Extraordinaries)	-2.01	-1.51	-1.62	-1.23	-0.63	-0.22	-0.10
EPS (Diluted)	-2.01	-1.51	-1.62	-1.23	-0.63	-0.22	-0.10
EBITDA	-119	-86	-69	-55	-26	-9	-3
Other After Tax Adjustments	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—
Shares Outstanding	60	57	43	42	41	43	43
Market Capitalization	1,577	792	596	319	577	—	—
Operating Lease Expense	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KAPLAN GILLA	Director	Mar 26 '26	Option Exercise	2.25	106,344	239,274	81,403	Mar 27
KAPLAN GILLA	Director	Mar 25 '26	Option Exercise	2.25	14,295	32,164	42,526	Mar 27
KAPLAN GILLA	Director	Mar 25 '26	Sale	36.97	14,295	528,506	28,231	Mar 27
Bensen Daniel	Chief Discovery Officer	Feb 12 '26	Sale	32.87	8,000	262,965	146,981	Feb 13
Bensen Daniel	Chief Discovery Officer	Jan 12 '26	Sale	28.52	8,000	228,185	154,981	Jan 20
MORE ROBERT J	Director	Dec 19 '25	Sale	25.00	10,000	250,000	3,823,425	Dec 19
Bensen Daniel	Chief Discovery Officer	Dec 12 '25	Sale	22.64	8,000	181,159	162,981	Dec 16
MORE ROBERT J	Director	Nov 21 '25	Sale	20.25	246,871	5,000,026	3,833,425	Nov 25
Bensen Daniel	Chief Operating Officer	Nov 19 '25	Sale	16.32	49,956	815,297	170,981	Nov 19
Bensen Daniel	Chief Operating Officer	Nov 18 '25	Sale	16.07	75,633	1,215,627	220,937	Nov 19
Bensen Daniel	Chief Operating Officer	Nov 17 '25	Sale	16.18	20,072	324,798	296,570	Nov 17
Bensen Daniel	Chief Operating Officer	Nov 14 '25	Sale	16.02	110,228	1,765,489	316,642	Nov 17
Bensen Daniel	Chief Operating Officer	Nov 13 '25	Sale	16.00	1,111	17,780	426,870	Nov 17
KAPLAN GILLA	Director	Jun 18 '25	Sale	9.78	9,568	93,596	28,231	Jun 20
KAPLAN GILLA	Director	Jun 17 '25	Sale	10.35	10	104	37,799	Jun 20

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.